Peter Schmid
Led KEYNOTE-522 and IMpassion130, the trials that brought immunotherapy into triple-negative breast cancer.
Overview
Peter Schmid was principal investigator of IMpassion130, the first positive immunotherapy trial in breast cancer, and of KEYNOTE-522, which showed neoadjuvant pembrolizumab with chemotherapy raises pathological complete response and improves event-free and overall survival in stage II-III TNBC. KEYNOTE-522 is now the global standard for early TNBC. He leads experimental cancer medicine at Barts and continues to run immunotherapy and ADC combination trials.
Pages like this
not linked directly; found by shared links- PersonMartin Reck
Shares Atezolizumab, Pembrolizumab, PD-1, Immune checkpoint inhibitors and the tags immunotherapy, trialist.
- PersonArjun V. Balar
Shares Atezolizumab, PD-L1, Pembrolizumab, PD-1 and the tag immunotherapy.
- PersonElizabeth A. Mittendorf
Shares Atezolizumab, Triple-negative breast cancer (TNBC), Immune checkpoint inhibitors and the tags tnbc, immunotherapy.
- PersonBrian I. Rini
Shares Pembrolizumab, PD-1, Immune checkpoint inhibitors and the tags immunotherapy, trialist.
- PersonCaroline Robert
Shares Pembrolizumab, PD-1, Immune checkpoint inhibitors and the tags immunotherapy, trialist.
- PersonJedd D. Wolchok
Shares PD-1, Immune checkpoint inhibitors and the tags immunotherapy, trialist.
- PersonJoaquim Bellmunt
Shares Pembrolizumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonGordon J. Freeman
Shares PD-L1, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.